Quarterly Financial Results: Contains consolidated financial statements for the nine-month period ended December 31, 2025 (Q3 of fiscal year 2026), including income statements, balance sheets, cash flow statements, and statements of equity with comparative prior-year periods Product and Service Revenue Breakdown: Reports revenue segmented between Products and Services for both the quarterly…

Our analysis rates this filing CAUTIOUS. STERIS plc faces an ELEVATED concern level (6.8/10) driven by three material developments: the completed divestiture of its Dental segment, ongoing multi-year restructuring charges, and multiple acquisition integrations occurring simultaneously. The Dental…

Concern level: HIGH (6.8/10). Key factors: Material Dental segment divestiture completed June 30, 2025 - represents loss of revenue stream and one-time charges impacting Q3 FY2026 results (severity 7/10); Multi-year restructuring program (FY2024-2025) with ongoing severance, contract termination, and product rationalization costs indicating sustained operational inefficiencies (severity 6/10);…

Notable risk changes: Dental segment divested June 30, 2025 - material loss on sale and discontinued operations charges affecting Q3 FY2026 results; represents loss of revenue stream and strategic repositioning; Multi-year restructuring program (FY2024-2025) with ongoing severance, contract termination, and product rationalization costs indicates operational inefficiencies requiring significant restructuring;…

The model predicts STE will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.